NCT00168701已完成2 期
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 260
- 试验地点
- 73
- 主要终点
- The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.
研究概览
简要总结
Determine the efficacy, safety, and tolerability of BG00012 in MS patients.
详细描述
The study will be divided into two parts: Part 1 will be a 24-week, blinded, placebo-controlled treatment phase followed by Part 2, a 24-week blinded, safety extension phase in which all subjects will receive BG00012.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be 18 to 55 years old, inclusive, at the time of informed consent.
- •Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 (McDonald et al, 2001; Appendix 2).
- •Must have a baseline EDSS between 0.0 and 5.0, inclusive.
- •Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.
- •Male and female subjects must be willing to take appropriate measures to prevent pregnancy.
排除标准
- •Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 [Appendix 3]).
- •History of malignancy.
- •History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
- •History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.
- •History of human immunodeficiency virus (HIV).
- •History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.
- •An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.
- •Body weight >100 kg.
- •Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.
- •Any of the following abnormal blood tests at screening.
- •Any previous treatment with FUMADERM®, FAG-201, or BG
- •A medication history that precludes entry into the study.
- •Female subjects who are currently pregnant or breast-feeding.
结局指标
主要结局
The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.
时间窗: Weeks 12, 16, 20, and 24
次要结局
- The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12 weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.(Weeks 24 and 48)
研究者
研究点 (73)
Loading locations...
相似试验
已完成
1 期
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male VolunteersHealthy VolunteersNCT02452996GeNeuro Innovation SAS21
已完成
3 期
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisNCT00420212Biogen1,234
已完成
3 期
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisNCT00451451Biogen1,417
已完成
1 期
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese ParticipantsHealthy VolunteersNCT05805904Bristol-Myers Squibb24
终止
1 期
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection FractionHeart FailureNCT03281122Bristol-Myers Squibb199